Center for Pharmacogenetics and Department of Pharmaceutical Sciences, University of Pittsburgh, Pittsburgh, PA, United States.
Front Immunol. 2024 Apr 15;15:1392099. doi: 10.3389/fimmu.2024.1392099. eCollection 2024.
Asparaginase (ASNase) is a crucial part of acute leukemia treatment, but immune responses to the agent can reduce its effectiveness and increase the risk of relapse. Currently, no reliable and validated biomarker predicts ASNase-induced hypersensitivity reactions during therapy. We aimed to identify predictive biomarkers and determine immune cells responsible for anaphylaxis using a murine model of ASNase hypersensitivity.
Our preclinical study uses a murine model to investigate predictive biomarkers of ASNase anaphylaxis, including anti-ASNase antibody responses, immune complex (IC) levels, ASNase-specific binding to leukocytes or basophils, and basophil activation.
Our results indicate that mice immunized to ASNase exhibited dynamic IgM, IgG, and IgE antibody responses. The severity of ASNase-induced anaphylaxis was found to be correlated with levels of IgG and IgE, but not IgM. Basophils from immunized mice were able to recognize and activate in response to ASNase ex vivo, and the extent of recognition and activation also correlated with the severity of anaphylaxis observed. Using a multivariable model that included all biomarkers significantly associated with anaphylaxis, independent predictors of ASNase-induced hypersensitivity reactions were found to be ASNase IC levels and ASNase-specific binding to leukocytes or basophils. Consistent with our multivariable analysis, we found that basophil depletion significantly protected mice from ASNase-induced hypersensitivity reactions, supporting that basophils are essential and can be used as a predictive marker of ASNase-induced anaphylaxis.
Our study demonstrates the need for using tools that can detect both IC- and IgE-mediated hypersensitivity reactions to mitigate the risk of ASNase-induced hypersensitivity reactions during treatment.
天冬酰胺酶(ASNase)是急性白血病治疗的关键部分,但机体对该药物的免疫反应会降低其疗效并增加复发风险。目前,尚无可靠且经过验证的生物标志物可预测治疗过程中 ASNase 诱导的过敏反应。我们旨在使用 ASNase 过敏反应的小鼠模型来鉴定预测性生物标志物并确定引起过敏反应的免疫细胞。
我们的临床前研究使用小鼠模型来研究 ASNase 过敏反应的预测性生物标志物,包括抗 ASNase 抗体反应、免疫复合物(IC)水平、ASNase 与白细胞或嗜碱性粒细胞的特异性结合以及嗜碱性粒细胞活化。
我们的结果表明,免疫接种 ASNase 的小鼠表现出动态 IgM、IgG 和 IgE 抗体反应。发现 ASNase 诱导的过敏反应的严重程度与 IgG 和 IgE 水平相关,但与 IgM 无关。来自免疫接种小鼠的嗜碱性粒细胞能够识别并对 ASNase 进行体外激活,并且识别和激活的程度也与观察到的过敏反应的严重程度相关。使用包含与过敏反应显著相关的所有生物标志物的多变量模型,发现 ASNase 诱导的超敏反应的独立预测因子是 ASNase IC 水平和 ASNase 与白细胞或嗜碱性粒细胞的特异性结合。与我们的多变量分析一致,我们发现嗜碱性粒细胞耗竭可显著保护小鼠免受 ASNase 诱导的过敏反应,这表明嗜碱性粒细胞是必需的,并且可以作为 ASNase 诱导的过敏反应的预测标志物。
我们的研究表明需要使用能够检测 IC 和 IgE 介导的超敏反应的工具来降低治疗过程中 ASNase 诱导的超敏反应的风险。